Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis
Open Access
- 19 February 2024
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 16 (1) , 1-15
Abstract
Background: Drug resistance in tuberculosis (TB) poses a major ongoing challenge to public health. The recent inclusion of bedaquiline into TB drug regimens has improved treatment outcomes, but this advance is threatened by the emergence of strains of Mycobacterium tuberculosis (Mtb) resistant to bedaquiline. Clinical bedaquiline resistance is most frequently conferred by off-target resistance-associated variants (RAVs) in the mmpR5 gene (Rv0678), the regulator of an efflux pump, which can also confer cross-resistance to clofazimine, another TB drug. Methods: We compiled a dataset of 3682 Mtb genomes, including 180 carrying variants in mmpR5, and its immediate background (i.e. mmpR5 promoter and adjacent mmpL5 gene), that have been associated to borderline (henceforth intermediate) or confirmed resistance to bedaquiline. We characterised the occurrence of all nonsynonymous mutations in mmpR5 in this dataset and estimated, using time-resolved phylogenetic methods, the age of their emergence. Results: We identified eight cases where RAVs were present in the genomes of strains collected prior to the use of bedaquiline in TB treatment regimes. Phylogenetic reconstruction points to multiple emergence events and circulation of RAVs in mmpR5, some estimated to predate the introduction of bedaquiline. However, epistatic interactions can complicate bedaquiline drug-susceptibility prediction from genetic sequence data. Indeed, in one clade, Ile67fs (a RAV when considered in isolation) was estimated to have emerged prior to the antibiotic era, together with a resistance reverting mmpL5 mutation. Conclusions: The presence of a pre-existing reservoir of Mtb strains carrying bedaquiline RAVs prior to its clinical use augments the need for rapid drug susceptibility testing and individualised regimen selection to safeguard the use of bedaquiline in TB care and control.Keywords
Funding Information
- Wellcome Trust (203583/Z/16/Z, 203919/Z/16/Z)
- Biotechnology and Biological Sciences Research Council (BB/R01356X/1)
- University College London (Excellence Fellowship)
This publication has 88 references indexed in Scilit:
- Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence areaeLife, 2015
- Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineageNature Genetics, 2015
- A robust SNP barcode for typing Mycobacterium tuberculosis complex strainsNature Communications, 2014
- Acquired Resistance of Mycobacterium tuberculosis to BedaquilinePLOS ONE, 2014
- Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2014
- From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices PipelineCurrent Protocols in Bioinformatics, 2013
- Improving the Accuracy of Demographic and Molecular Clock Model Comparison While Accommodating Phylogenetic UncertaintyMolecular Biology and Evolution, 2012
- Antibiotic resistance is ancientNature, 2011
- Rates and Mechanisms of Resistance Development inMycobacterium tuberculosisto a Novel Diarylquinoline ATP Synthase InhibitorAntimicrobial Agents and Chemotherapy, 2010
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005